Geisinger will expand its precision medicine project beyond research to preventive care, the Danville, PA-based integrated health system announced Sunday. The project already reports clinically actionable genomic results to research participants and their primary care physicians, and plans to launch a clinical DNA pilot program with 1,000 patients in the next six months. “Understanding the genome warning signals of every patient will be an essential part of wellness planning and health management,” Geisinger President and CEO David Feinberg, M.D., told participants at the HLTH Conference in Las Vegas. “Geisinger patients will be able to work with their family physician to modify their lifestyle and minimize risks that may be revealed.”